Carbonic anhydrase IX as an anticancer therapy target: Preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain

Current Pharmaceutical Design

Volumn 16, Issue 29, 2010, Pages 3255-3263

  Zatovicova, M ^a   Jelenska, L ^a   Hulikova, A ^a   Csaderova, L ^b   Ditte, Z ^a   Ditte, P ^a   Goliasova, T ^a   Pastorek, J ^a   Pastorekova, S ^a,b  

^a Institute of Virology   (Slovakia)

^b INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Cancer; Carbonic anhydrase IX; Hypoxia; Immunotherapy; Monoclonal antibody

Indexed keywords

ACETAZOLAMIDE; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; CELECOXIB; CELL SURFACE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONCLONAL ANTIBODY VII 32; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; MONOCLONAL ANTIBODY IV 18; MONOCLONAL ANTIBODY M75; MONOCLONAL ANTIBODY V 10; MONOCLONAL ANTIBODY V 12; MONOCLONAL ANTIBODY VII 20; MONOCLONAL ANTIBODY VII 38; SULFONAMIDE; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VALDECOXIB;

ACIDOSIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CATALYSIS; CELL ADHESION; CELL DENSITY; CELL HYPOXIA; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMPETITIVE INHIBITION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; IMMUNOBLOTTING; KIDNEY CARCINOMA; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CATALYTIC DOMAIN; COLORECTAL NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78649813619     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793429832     Document Type: Article

References (57)

1. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7: 168-81.
2. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004; 19: 199-229.
3. Pastorekova S, Pastorek J. Cancer-related carbonic anhydrase isozymes and their inhibition. In: Supuran CT, Scozzafava A, Conway J, Eds. Carbonic anhydrase, its inhibitors and activators. Boca Raton-London-New York-Washington DC: CRC Press 2004; pp. 253-272.
4. Pastorekova S, Parkkila S, Zavada J. Tumor-associated carbonic anhydrases and their clinical significance. Adv Ćlin Chem 2006; 42: 167-216.
5. Pastorekova S, Parkkila S, Parkkila AK, et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementery DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997; 112: 398-408.
6. Saarnio J, Parkkila S, Parkkila AK, et al. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J Histochem Cytochem 1998; 46: 497-504.
7. Wykoff C, Beasley N, Watson P, et al. Hypoxia-inducible regulation of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 7075-83.
8. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
9. Kaluz S, Kaluzova M, Chrastina A, et al. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1?? stabilization: a role for phosphatidylinositol 3-kinase. Cancer Res 2002; 62: 4469-77.
10. Ihnatko R, Kubes M, Takacova M, et al. Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol 2006; 29: 1025-33.
11. Rafajova M, Zatovicova M, Kettmann R, Pastorek J, Pastorekova S. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol 2004; 24: 995-1004.
12. Zatovicova M, Sedlakova O, Svastova E, et al. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer 2005; 93: 1267-76.
13. Pastorek J, Pastorekova S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and putative helix-loop-helix DNA binding segment. Oncogene 1994; 9: 2877-88.
14. Opavsky R, Pastorekova S, Zelnik V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996; 33: 480-7.
15. Hilvo M, Baranauskiene L, Salzano AM, et al. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 2008; 283: 27799-809.
16. Innocenti A, Pastorekova S, Pastorek J, Scozzafava A, De Simone G, Supuran CT. The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors. Bioorg Med Chem Lett 2009; 19: 5825-8.
17. Hulikova A, Zatovicova M, Svastova E, et al. Intact intracellular tail is critical for proper functioning of the tumor-associated, hypoxia-regulated carbonic anhydrase IX. FEBS Lett 2009; 583: 3563-8.
18. Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur J Cancer 2005; 41: 2935-47.
19. Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992; 187: 620-6.
20. Alterio V, Hilvo M, Di Fiore A, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci U S A 2009; 106: 16233-8.
21. Svastova E, Zilka N, Zatovicova M, et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β-catenin. Exp Cell Res 2003; 290: 332-45.
22. Zavadova Z, Zavada J. Carbonic anhydrase IX (CA IX) mediates tumor cell interactions with microenvironment. Oncol Rep 2005; 13: 977-82.
23. Svastova E, Hulikova A, Rafajova M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004; 577: 439-95.
24. Swietach P, Wigfield S, Supuran CT, Harris AL, Vaughan-Jones RD. Cancer-associated, hypoxia-inducible carbonic anhydrase IX facilitates CO2 diffusion. BJU Int 2008; 101 (Suppl 4): 22-4.
25. Swietach P, Patiar S, Supuran CT, Harris AL, Vaughan-Jones RD. The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J Biol Chem 2009; 284: 20299-310.
26. Innocenti A, Vullo D, Scozzafava A, Casey JR, Supuran C. Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett 2005; 15: 573-8.
27. Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 2008; 14: 685-98.
28. Chiche J, Ilc K, Laferriere J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009; 69: 358-68.
29. Casini A, Scozzafava A, Mastrolorenzo A, Supuran LT. Sulfonamides and sulfonylated derivatives as anticancer agents. Curr Cancer Drug Targets 2002; 2: 55-75.
30. Saczewski F, Slawinski J, Kornicka A, et al. Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors. Bioorg Med Chem Lett 2006; 16: 4846-51.
31. Weber A, Casini A, Heine A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 2004; 47: 550-7.
32. Winum JY, Vullo D, Casini A, Montero JL, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J Med Chem 2003; 46: 2197-204.
33. Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumorassociated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 2005; 48: 4834-41.
34. Dubois L, Douma K, Supuran CT, et al. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother Oncol 2007; 83: 367-73.
35. Dubois L, Lieuwes NG, Maresca A, et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)- oxygenated cells in a xenograft tumour model. Radiother Oncol 2009; 92: 423-8.
36. Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res 1993; 13: 1549-56.
37. Ahlskog JK, Dumelin CE, Trussel S, Marlind J, Neri D. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett 2009; 19: 4851-6.
38. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-11.
39. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986; 38: 489-94.
40. Oosterwijk, E. Carbonic anhydrase IX: historical and future perspectives. BJU Int 2008; 101 (Suppl 4): 2-7
41. Ahlskog JK, Schliemann C, Marlind J, et al. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer 2009; 101: 645-57.
42. Xu C, Lo A, Yammanuru A, et al. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One 2010; 5: e9625.
43. Zatovicova M, Tarabkova K, Svastova E, et al. Monoclonal antibodies generated in CA IX-deficient mice recognize different domains of tumor-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods 2003; 282: 117-34.
44. Grant BD, Donaldson JG. Pathways and mechanisms of endocytic recycling. Nat Rev Mol Cell Biol 2009; 10: 597-608.
45. Jaracz S, Chen J, Kuznetsova LV, Ojima I: Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem 2005; 13: 5043-54.
46. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006; 56: 226-243
47. Vaidyanathan G, Affleck GJ, Bigner DD, Zalutskya MR. Nsuccinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At. Nucl Med Biol 2003; 30: 351-9.
48. Shiota M, Ikeda Y, Kaul Z, Itadani J, Kaul SC, Wadhwa R. Internalizing antibody-based targeted gene delivery for human cancer cells. Hum Gene Ther 2007; 18:1153-60.
49. Bianco R, Daniele G, Ciardiello F, Tortora G. Monoclonal antibodies targeting the epidermal growth factor receptor. Curr Drug Targets 2005; 6: 275-87.
50. Liu Z, Smyth FE, Renner C, Lee FT, Oosterwijk E, Scott AM. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2002; 51: 171-7.
51. Davis ID, Liu Z, Saunders W, et al. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun 2007; 7: 14.
52. Haugh JM. Localization of receptor-mediated signal transduction pathways: the inside story. Mol Interven 2002; 2: 292-303.
53. Kaelin WG. Von hippel-lindau diease. Annu Rev Pathol 2007; 2: 145-73.
54. Bartosova M, Parkkila S, Pohlodek K, et al. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol 2002; 197: 314-21.
55. Cecchi A, Supuran CT. Fluorescence- and spin-labeled carbonic anhydrase inhibitors. Curr Pharm Des 2008; 14(7): 699-707.
56. Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 2008; 14(7): 685-698.
57. Winum JY, Scozzafava A, Montero JL, Supuran CT. Design of zinc binding functions for carbonic anhydrase inhibitors. Curr Pharm Des 2008; 14(7): 615-621